Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma

被引:102
作者
Jackson, A
Jayson, GC
Li, KL
Zhu, XP
Checkley, DR
Tessier, JJL
Waterton, JC
机构
[1] Univ Manchester, Stopford Med Sch, Div Imaging Sci & Biomed Engn, Manchester M13 9PT, Lancs, England
[2] Christie Hosp NHS Trust, Canc Res Campaign Dept Med Oncol, Manchester M20 4BX, Lancs, England
[3] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
关键词
D O I
10.1259/bjr/70653746
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We have investigated the reproducibility of dynamic contrast enhanced imaging techniques in nine patients with cerebral glioma. Patients were imaged twice with a 2 day interval between scans. Maps were produced of the time taken to achieve 90% enhancement (T90), the maximal intensity change per time interval ratio (MITR), the volume transfer coefficient between plasma and the extravascular extracellular space (K-trans) and the extravascular extracellular contrast distribution volume, nu(e). Measurements of K-trans greater than 1.2 min(-1) were used to exclude pixels where first pass perfusion effects dominated the measurement. Measures of the test-retest coefficient of variation (CoV) and intraclass correlation coefficients were used to assess reproducibility for measurements from a volume of interest containing enhancing tissue from the whole tumour. MITR showed poor reproducibility (mean CoV 17.9%, 95% confidence limits for group comparisons 20.2%). T90 showed good reproducibility (mean CoV 7.1%, 95% confidence limits for group comparisons 5.2%). Calculated values of K-trans and nu(e) also showed good reproducibility (mean CoV 7.7% and 6.2% respectively, 95% confidence limits for group comparisons 6.2% and 4.8%, respectively). We conclude that the measurements of K-trans and nu(e) derived from pharmacokinetic analysis are sufficiently reproducible to support their use as a biological markers in therapeutic trials.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 43 条
[1]  
Amoroso A, 1997, Eur Rev Med Pharmacol Sci, V1, P17
[2]   MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report [J].
Brasch, R ;
Turetschek, K .
EUROPEAN JOURNAL OF RADIOLOGY, 2000, 34 (03) :148-155
[3]   Assessing tumor angiogenesis using macromolecular MR imaging contrast media [J].
Brasch, R ;
Pham, C ;
Shames, D ;
Roberts, T ;
vanDijke, K ;
vanBruggen, N ;
Mann, J ;
Ostrowitzki, S ;
Melnyk, O .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1997, 7 (01) :68-74
[4]   PHARMACOKINETIC PARAMETERS IN CNS GD-DTPA ENHANCED MR IMAGING [J].
BRIX, G ;
SEMMLER, W ;
PORT, R ;
SCHAD, LR ;
LAYER, G ;
LORENZ, WJ .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1991, 15 (04) :621-628
[5]   Non-invasive vascular imaging: assessing tumour vascularity [J].
Delorme, S ;
Knopp, MV .
EUROPEAN RADIOLOGY, 1998, 8 (04) :517-527
[6]   Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions [J].
denBoer, JA ;
Hoenderop, RKKM ;
Smink, J ;
Dornseiffen, G ;
Koch, PWAA ;
Mulder, JH ;
Slump, CH ;
Volker, EDP ;
deVos, RAI .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1997, 7 (04) :702-715
[7]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[8]   DIFFERENTIATION OF BENIGN FROM MALIGNANT BREAST MASSES BY TIME-INTENSITY EVALUATION OF CONTRAST-ENHANCED MRI [J].
FLICKINGER, FW ;
ALLISON, JD ;
SHERRY, RM ;
WRIGHT, JC .
MAGNETIC RESONANCE IMAGING, 1993, 11 (05) :617-620
[9]   Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis [J].
Galbraith, SM ;
Lodge, MA ;
Taylor, NJ ;
Rustin, GJS ;
Bentzen, S ;
Stirling, JJ ;
Padhani, AR .
NMR IN BIOMEDICINE, 2002, 15 (02) :132-142
[10]   Cerebral blood volume maps with dynamic contrast-enhanced T1-weighted FLASH imaging: Normal values and preliminary clinical results [J].
Hacklander, T ;
Hofer, M ;
Reichenbach, JR ;
Rascher, K ;
Furst, G ;
Modder, U .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1996, 20 (04) :532-539